Fig. 6
From: Selective SERCA2a activator as a candidate for chronic heart failure therapy
In vivo effects following oral treatment in STZ rats (40 mg/kg compound 8). Rats were treated with 1 or 4 oral daily doses of compound 8 (40 mg/kg) or saline, accordingly to the protocol shown in Additional file 1: Figure S2. Echocardiographic parameters (see also Additional file 1: Figure S4) were measured in each group 60-min post treatment under ketamine/pentobarbital anesthesia; each measurement was normalized to its basal value to highlight changes between experimental groups (saline and 40 mg/kg compound 8). Data are mean ± SEM; saline N = 21, 40 mg/kg compound 8 N = 22. *p < 0.05 vs saline group for the interaction factor in RM two-way ANOVA